Evaxion Biotech A/S saw its shares surge more than 27% Thursday after announcing that Merck & Co. has exercised its option to license the Danish biotech's vaccine candidate EVX-B3. The Nasdaq-listed stock climbed to $4.20, gaining $0.79 from its previous close of $3.30, with trading volume spiking to 71.4 million shares—far exceeding its average volume of approximately 92,000 shares.

The licensing agreement includes a $7.5 million upfront payment to Evaxion, with potential development, regulatory and sales milestone payments reaching up to $592 million. Merck, known as MSD outside the United States, will also pay royalties on net sales and assume full responsibility for all future development costs of the preclinical vaccine candidate. The deal extends Evaxion's cash runway into the first half of 2027.

EVX-B3 targets an undisclosed pathogen associated with repeated infections, increasing incidence and serious medical complications. Both companies have maintained secrecy around the specific disease target, noting only that no vaccines currently exist for the condition. The candidate was discovered using Evaxion's AI-Immunology platform, which identifies novel targets that might otherwise remain undiscovered.

The collaboration represents a significant validation of Evaxion's technology platform, according to company executives. "This has significant financial value for us, but equally important is the massive validation of our AI-Immunology platform by MSD, the world leader in vaccine development and commercialization," said Birgitte Rønø, Evaxion's chief scientific officer and interim CEO. The companies have also extended the evaluation period for another vaccine candidate, EVX-B2, which targets gonorrhea, with a licensing decision expected in the first half of 2026.

Mjällby AIF stands on the brink of securing the Swedish Allsvenskan championship, with their fate potentially decided during Sunday's heated Stockholm derby between Hammarby and AIK. The southern Swedish club could clinch the title without even playing if Hammarby drops points against their city rivals. This unprecedented scenario has created intense anticipation across Swedish football as the season reaches its dramatic conclusion.

In Bromölla, Mjällby's supporter club Sillastrybarna gathered at a restaurant to watch the Stockholm derby together, reflecting the nervous excitement surrounding the potential championship. "The feeling is that anything could happen today, but we're satisfied either way," said Kristofer Rasmusson, vice chairman of Sillastrybarna. The supporters acknowledged that while winning the title during another team's match would be unusual, it would still represent a remarkable achievement for the club.

Should Hammarby secure victory against AIK on Sunday, Mjällby's championship aspirations would extend to Monday's away match against IFK Göteborg. In that scenario, Mjällby would need to defeat the Gothenburg side to claim the SM-gold. Maximilian Damm, who is live-reporting on Mjällby's title chase, expressed confidence in the team's abilities, stating, "As soon as they get to play a match. That is, on Monday against IFK Göteborg away. It's hard not to be impressed by how MAIF approaches matches, and there's no reason not to believe they won't win on Monday."

The Monday encounter against IFK Göteborg presents its own challenges, with historical data showing low-scoring affairs between the two clubs. The last five meetings have produced just one goal per match, with Mjällby holding three victories to IFK's two. Despite this history, both teams have significant motivation - Mjällby for the championship and IFK Göteborg for European qualification spots and honor. The match kicks off Monday at 19:10, potentially crowning a new Swedish champion.